Evaluation of the Clinical Safety and Efficacy of the 34/38 mm Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Subjects According to the Indication for Use
Latest Information Update: 12 Oct 2023
At a glance
- Drugs Zotarolimus (Primary)
- Indications Arteriosclerosis; Cardiovascular disorders; Coronary artery disease; Ischaemic heart disorders
- Focus Therapeutic Use
- 09 Oct 2023 Status changed from active, no longer recruiting to completed.
- 11 Apr 2023 Planned End Date changed from 30 Dec 2023 to 30 Apr 2023.
- 12 Jun 2018 Planned primary completion date changed from 30 May 2018 to 31 Jul 2018.